sometimes a single worry grows so large that it obscures all the good things happening at the same time that’s the case with the stock of pharma giant abbvie whose blockbuster drug humira faces patent expirations humira is an immunosuppressive that’s racked up nearly 200 billion in sales since its 2002 approval abbvie ticker abbv has fought fiercely to extend its exclusivity of humira which treats conditions from rheumatoid arthritis to crohn’s disease but it has already lost patent protection in europe and faces increased competition from biosimilars in the us beginning next year